Search

everythinglearnresearchcommunity

for

Search:↓

The early genes of a specific virus can cause abnormal skin cell growth and hair follicle changes.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Timely diagnosis and treatment of complex autoimmune diseases like APS2 are crucial to prevent complications and improve life quality.

TNF-α inhibitors may cause complete hair loss in some patients with ankylosing spondylitis.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.

Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.

Autoimmune myopathy may be linked to hair loss and skin depigmentation.

Itching can be an early sign of hyperthyroidism.

Sintilimab treatment caused hair loss but led to complete tumor remission.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

PTHrP and its receptor can control blood vessel growth and hair development in mouse skin.

Adalimumab may cause severe hair loss in some patients.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.

Specific mutations in a receptor cause facial abnormalities and hair loss.

Autoimmune conditions can be linked to trichoepitheliomas, with treatment focusing on cosmetic concerns.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

T-cell reconstitution after thymus transplantation can cause hair whitening and loss.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Noncoding dsRNA boosts hair growth by activating TLR3 and increasing retinoic acid.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Regulatory T cells adapt to different environments to control inflammation and support tissue repair.

Thymosin β4 helps with healing, inflammation, and organ protection.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

CTP-543 is generally safe for treating alopecia areata.

Etanercept may not prevent alopecia areata from coming back.